Bastian F.
- Country
- Germany
- Department
- Zentrum
Research Overview
- Phase 3 Randomized Open-label Study of Imlunestrant, Abemaciclib, and Endocrine Therapy in ER+ HER2- Advanced Breast Cancer Post-Endocrine Treatment
- Phase IV Study of Abemaciclib and Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer with Digital Side Effect Management
- Phase 3 Randomized Trial of Acalabrutinib, Obinutuzumab, and Venetoclax in High-Risk Chronic Lymphocytic Leukemia Patients
Data & Insights
Has run more than one trial at 25 of 234 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating polycythemia vera with particular focus on understanding treatment resistance patterns. Their expertise extends to studying hydroxyurea resistance using innovative artificial intelligence approaches.
- Treatment-resistant blood disorders
- AI-driven therapeutic predictions
- Myeloproliferative disorders
Breast Cancer Treatment
The investigator focuses on advanced therapeutic approaches for hormone receptor-positive HER2-negative breast cancer. Their work encompasses both locally advanced and metastatic disease states, with particular attention to endocrine therapy combinations.
- Novel endocrine therapy approaches
- Targeted combination treatments
- Digital side effect management
Leukemia Research
The investigator specializes in treating high-risk chronic lymphocytic leukemia, particularly focusing on cases involving genetic mutations. Their expertise includes developing targeted combination therapies for patients with complex karyotype and specific genetic deletions.
- Novel therapeutic combinations
- Genetic mutation analysis
- High-risk patient treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.